\nStrengthening Life Sciences and Infectious Diseases Activities at Genopole, with Synergies in Virology, Biosafety, and Biological Control<\/i><\/p>
WOIPPY, France--(BUSINESS WIRE)--Regulatory News:<\/p>
\nABL Diagnostics (Euronext Paris \u2013 Compartment B \u2013 ISIN: FR001400AHX6), a company specialized in molecular diagnostics, healthcare software, and clinical sample management, announces that it has been selected by the \u00c9vry Commercial Court to acquire the assets and business operations of TEXCELL.<\/p>
\nThis decision follows the industrial plan submitted by ABL Diagnostics aimed at ensuring business continuity, preserving recognized scientific expertise, and developing complementarities with the Group\u2019s existing activities in the fields of molecular diagnostics, virology, and infectious diseases.<\/p>
\nScope of the acquisition:<\/b><\/p>
\nThe transaction notably provides for:<\/p>
\nTEXCELL originated from the scientific ecosystem of the Institut Pasteur and has recognized expertise in viral safety, biosafety, genomic analysis, immunological monitoring, and services dedicated to biotechnology and innovative therapies.<\/p>
\nAccording to publicly available information, TEXCELL France generated revenue of approximately \u20ac5.4 million in 2024, following \u20ac6.2 million in 2023 and \u20ac7.5 million in 2022.<\/p>
\nFinancial terms of the transaction:<\/b><\/p>
\nThe overall economic value of the project is estimated at approximately \u20ac2.9 million, including:<\/p>
\nThe Company indicates that the transaction is financed from the Group\u2019s available financial resources. The terms of the accepted offer are set out in the documents filed with the \u00c9vry Commercial Court as part of the sale process.<\/p>
\nStrategic continuity with Institut Pasteur:<\/b><\/p>
\nThis transaction is part of the strategic initiatives recently undertaken by ABL Diagnostics with the Institut Pasteur in Paris (HPV RNA-Seq genotyping project).<\/p>
\nThe acquisition of TEXCELL, whose origins are historically linked to the Institut Pasteur, further strengthens the scientific consistency of this strategy focused on innovation, virology, and infectious diseases.<\/p>
\nScientific and technological complementarities:<\/b><\/p>
\nTEXCELL\u2019s expertise in viral safety, biological control, cell culture, viral characterization, and biosafety is complementary to the UltraGene, DeepChek\u00ae, and Nadis\u00ae platforms developed by ABL Diagnostics.<\/p>
\nStrategic presence at Genopole \u00c9vry:<\/b><\/p>
\nThe acquisition gives ABL Diagnostics an operational presence within Genopole \u00c9vry-Courcouronnes.<\/p>
\nThe Company plans to progressively strengthen the site\u2019s workforce through the recruitment of approximately five additional employees to support scientific activities from TEXCELL.<\/p>
\nResearch and development program:<\/b><\/p>
\nABL Diagnostics intends to continue the scientific valorization of the acquired assets.<\/p>
\nThe characterized virus banks, cell line collections, virology expertise, and biosafety infrastructures represent valuable resources that may support the future development of new tools for biomedical research, biological quality control, and molecular diagnostics.<\/p>
\nStatement from the Chief Executive Officer:<\/b><\/p>
\nDr. Chalom Sayada, Chief Executive Officer of ABL Diagnostics, commented:<\/p>
\n\u201cTEXCELL brings ABL Diagnostics recognized scientific expertise, qualified teams, an established international brand, as well as technological and biological assets that complement our historical activities. This acquisition strengthens our presence in the fields of virology, biosafety, and services dedicated to biopharmaceutical companies.<\/p>
\nThis transaction is fully aligned with ABL Diagnostics\u2019 long-term strategy to strengthen its position among the leading international players in molecular biology, virology, and infectious diseases. For many years, our development has been driven by a combination of internal innovation, proprietary technology development, and targeted external growth operations.<\/p>
\nThe acquisition of TEXCELL illustrates the determination of management and the Board of Directors to continue executing this strategy by leveraging best-in-class technologies, differentiated expertise, and internationally recognized platforms. TEXCELL\u2019s expertise, historically rooted in the Institut Pasteur scientific ecosystem, is particularly complementary to our activities and recent strategic partnerships.<\/p>
\nWe plan to invest in automation, infrastructure modernization, team expansion, and the development of scientific activities in order to sustainably support laboratories, research centers, biotech companies, and healthcare industry players worldwide.\u201d<\/p>
\nSubject to the completion of the applicable legal and administrative formalities, ABL Diagnostics will provide further information in due course regarding the integration of the acquired activities and their inclusion in its strategic roadmap and objectives for fiscal year 2026.<\/p>
\nRegulated information:<\/b><\/p>
\nThis press release contains inside information within the meaning of Article 7 of Regulation (EU) No. 596\/2014 (Market Abuse Regulation \u2013 MAR). It is disclosed in accordance with Article 17 of MAR.<\/p>
\nThe forward-looking statements contained in this document are inherently subject to risks and uncertainties, including those relating to the outcome of legal proceedings and the approval of third parties.<\/p>
\nAbout ABL Diagnostics (ABLD)<\/b><\/p>
\nABL Diagnostics (ABLD) is an international company that specializes in innovative molecular biology tests and global solutions for its customers:<\/p>
\nABL Diagnostics<\/p>","protected":false},"excerpt":{"rendered":"
Strengthening Life Sciences and Infectious Diseases Activities at Genopole, with Synergies in Virology, Biosafety, and Biological ControlWOIPPY, France–(BUSINESS WIRE)–Regulatory News:
\nABL Diagnostics (Euronext Paris \u2013 Compartment B \u2013 ISIN: FR001400…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-43043","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/43043","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=43043"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/43043\/revisions"}],"predecessor-version":[{"id":43044,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/43043\/revisions\/43044"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=43043"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=43043"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=43043"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}